0000000000222203
AUTHOR
Rebeca Mirón Mombiela
sj-docx-1-uix-10.1177_01617346211029656 – Supplemental material for Diagnostic Performance of Muscle Echo Intensity and Fractal Dimension for the Detection of Frailty Phenotype
Supplemental material, sj-docx-1-uix-10.1177_01617346211029656 for Diagnostic Performance of Muscle Echo Intensity and Fractal Dimension for the Detection of Frailty Phenotype by Rebeca Mirón Mombiela, Jelena Vucetic, Paloma Monllor, Jenny S. Cárdenas-Herrán, Paloma Taltavull de La Paz and Consuelo Borrás in Ultrasonic Imaging
Development of an ultrasound-based muscle texture analysis as a potential imaging biomarker for frailty phenotype
Las herramientas habituales para evaluar la fragilidad muestran, entre otras características, una baja sensibilidad y un bajo valor predictivo positivo. Es por eso que, en este estudio prospectivo-retrospectivo, nos preguntamos si es posible identificar y desarrollar biomarcadores cuantitativos a partir de imágenes de ultrasonido muscular, para la identificación de sujetos con riesgo de fragilidad. Para ello utlilizamos el análisis de textura de ecointensidad con ayuda del aprendizaje automático (machine learning, en inglés) como enfoque experimental para responder a esta pregunta. El proyecto se desarrolló en consulta externa, donde se realizó la ecografía muscular. Al final de la adquisic…
sj-docx-1-uix-10.1177_01617346211029656 – Supplemental material for Diagnostic Performance of Muscle Echo Intensity and Fractal Dimension for the Detection of Frailty Phenotype
Supplemental material, sj-docx-1-uix-10.1177_01617346211029656 for Diagnostic Performance of Muscle Echo Intensity and Fractal Dimension for the Detection of Frailty Phenotype by Rebeca Mirón Mombiela, Jelena Vucetic, Paloma Monllor, Jenny S. Cárdenas-Herrán, Paloma Taltavull de La Paz and Consuelo Borrás in Ultrasonic Imaging
Ultrasonic Echo Intensity as a New Noninvasive In Vivo Biomarker of Frailty
Objectives To investigate whether muscle quality based on echo intensity (EI) is associated with muscle strength (MS) and correlates with risk of frailty in elderly outpatients. Design Cross-sectional, experimental study. Setting Outpatient clinic. Participants Individuals aged 20 to 90 (N = 112). Individuals aged 20 to 59 participated as controls. Those aged 60 and older participated in the experimental group and were subdivided into robust, prefrail, and frail according to the Fried frailty criteria. Measurements EI, muscle thickness (MT), and subcutaneous fat thickness (SFT) of the anterior compartment of the thigh were measured using ultrasound images. MS was quantified using a hand dyn…
Diagnostic Performance of Muscle Echo Intensity and Fractal Dimension for the Detection of Frailty Phenotype
To determine the relationship between muscle echo intensity (EI) and fractal dimension (FD), and the diagnostic performance of both ultrasound parameters for the identification of frailty phenotype. A retrospective interpretation of ultrasound scans from a previous cohort (November 2014–February 2015) was performed. The sample included healthy participants <60 years old, and participants ≥60 divided into robust, pre-frail, and frail groups according to Fried frailty criteria. A region of interest of the rectus femoris from the ultrasound scan was segmented, and histogram function was applied to obtain EI. For fractal analysis, images were processed using two-dimensional box-counting techniq…
Ultrasound Biomarkers for Sarcopenia: What Can We Tell So Far?
AbstractSarcopenia is a disease characterized by decreased skeletal muscle mass, strength, and loss of function that can impair quality of life and increase physical disability, adverse metabolic effects, and mortality. This review familiarizes the reader with ultrasound (US)-based biomarkers for sarcopenia with a discussion of these topics: why assessing sarcopenia is relevant for radiologists, how to evaluate muscle structure with US, the current challenges or pitfalls of these biomarkers, and the implications of all the available evidence. It summarizes the most up-to-date literature on the pathophysiology behind the use of these US-based biomarkers, the biomarkers themselves, and a prot…